After a 33-year odyssey, Jeffrey Bluestone grabs a ringside seat to watch his drug teplizumab go back into the clinic

Back in the fall of 2010, Eli Lilly wasted little time scuttling a slate of late-stage studies and walking away from a billion-dollar development deal as the pharma giant abruptly abandoned its diabetes drug teplizumab after watching the first pivotal go down in flames.

But when Lilly — then suffering one of the worst R&D droughts in its history — abandoned the drug and handed it all back to MacroGenics, which put it on the shelf and left it there, one scientist kept the faith.

Jeffrey Bluestone had started working on teplizumab in his lab in 1986, and he had lots of unanswered questions about the drug.

“It was as hard for me as anyone who was passionate about it, as might be expected,” says Bluestone.

In order to read this article, you must be an Endpoints News subscriber. (It's free to subscribe.)

← Go back

We produce two daily email newsletters designed to give you a complete picture of what's important in biopharma. It's free to subscribe and never any spam. Join 47,300+ biopharma executives who read Endpoints News every day.

Access is subject to the terms in our Privacy Policy.

The best place to read Endpoints News? In your inbox.

Comprehensive daily news report for those who discover, develop, and market drugs. Join 47,300+ biopharma pros who read Endpoints News by email every day.

Free Subscription

Research Scientist - Immunology
Recursion Pharmaceuticals Salt Lake City, UT
Director of Operations
Atlas Venture Cambridge, MA

Visit Endpoints Careers ->